


## Z4P

|                    |   |       |          |
|--------------------|---|-------|----------|
| Cat. No.:          | HY-153773   |       |          |
| CAS No.:           | 2361760-87-2  |       |          |
| Molecular Formula: | C <sub>19</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub> |       |          |
| Molecular Weight:  | 312.41  |       |          |
| Target:            | IRE1  |       |          |
| Pathway:           | Cell Cycle/DNA Damage   |       |          |
| Storage:           | Powder  | -20°C | 3 years  |
|                    |   | 4°C   | 2 years  |
|                    | In solvent  | -80°C | 6 months |
|                    |   | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

|   |  |                          |              |            |            |
|---|--|--------------------------|--------------|------------|------------|
| In Vitro  | DMSO : 100 mg/mL (320.09 mM; Need ultrasonic)  |                          |              |            |            |
|   |  | Solvent<br>Concentration | Mass<br>1 mg | 5 mg       | 10 mg      |
|   | Preparing Stock Solutions  | 1 mM                     | 3.2009 mL    | 16.0046 mL | 32.0092 mL |
|   |  | 5 mM                     | 0.6402 mL    | 3.2009 mL  | 6.4018 mL  |
| 10 mM   |  | 0.3201 mL                | 1.6005 mL    | 3.2009 mL  |            |
| Please refer to the solubility information to select the appropriate solvent. |  |                          |              |            |            |
| In Vivo   | 1. Add each solvent one by one: 10% DMSO >> 90% corn oil<br>Solubility: 2.5 mg/mL (8.00 mM); Clear solution; Need ultrasonic |                          |              |            |            |

### BIOLOGICAL ACTIVITY

|                           |   |
|---------------------------|---|
| Description               | Z4P is a BBB-permeable IRE1 inhibitor (IC <sub>50</sub> : 1.11 μM). Z4P inhibits Glioblastoma cell growth. Z4P prevents glioblastoma relapse when administered together with Temozolomide (HY-17364) <sup>[1]</sup> . |
| IC <sub>50</sub> & Target | IC50: 1.11 μM (IRE1) <sup>[1]</sup>   |

### REFERENCES

[1]. Pelizzari-Raymundo D, et al. A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment. iScience. 2023 Apr 24;26(5):106687.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA